{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:20:00Z","timestamp":1790274000276,"version":"4.1.0"},"reference-count":124,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["trilateral grant SCHA 1247\/3-1"],"award-info":[{"award-number":["trilateral grant SCHA 1247\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Targeting cancer cells using chimeric-antigen-receptor (CAR-)T cells has propelled adoptive T-cell therapy (ATT) to the next level. A plentitude of durable complete responses using CD19-specific CAR-T cells in patients suffering from various lymphoid malignancies resulted in the approval by the food and drug administration (FDA) of CD19-directed CAR-T cells for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). A substantial portion of this success in hematological malignancies can be traced back to the beneficial properties of the target antigen CD19, which combines a universal presence on target cells with no detectable expression on indispensable host cells. Hence, to replicate response rates achieved in ALL and DLBCL in the realm of solid tumors, where ideal target antigens are scant and CAR-T cells are still lagging behind expectations, the quest for appropriate target antigens represents a crucial task to expedite the next steps in the evolution of CAR-T-cell therapy. In this review, we want to highlight the potential of chondroitin sulfate proteoglycan 4 (CSPG4) as a CAR-target antigen for a variety of different cancer entities. In particular, we discuss merits and challenges associated with CSPG4-CAR-T cells for the ATT of melanoma, leukemia, glioblastoma, and triple-negative breast cancer.<\/jats:p>","DOI":"10.3390\/ijms20235942","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T10:57:27Z","timestamp":1574765847000},"page":"5942","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities\u2013Merits and Challenges"],"prefix":"10.3390","volume":"20","author":[{"given":"Dennis C.","family":"Harrer","sequence":"first","affiliation":[{"name":"Department of Dermatology, Universtit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Hartmannstra\u00dfe 14, 91052 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-0741","authenticated-orcid":false,"given":"Jan","family":"D\u00f6rrie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universtit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Hartmannstra\u00dfe 14, 91052 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8236-9298","authenticated-orcid":false,"given":"Niels","family":"Schaft","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universtit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Hartmannstra\u00dfe 14, 91052 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMc1800913","article-title":"CAR T-Cell Therapy in Large B-Cell Lymphoma","volume":"378","author":"Neelapu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41591-018-0212-6","article-title":"Tumors evading CARs-the chase is on","volume":"24","author":"Rafiq","year":"2018","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lesch, S., Benmebarek, M.R., Cadilha, B.L., Stoiber, S., Subklewe, M., Endres, S., and Kobold, S. (2019). Determinants of response and resistance to CAR T cell therapy. Semin. Cancer Biol.","DOI":"10.1016\/j.semcancer.2019.11.004"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1064","DOI":"10.1002\/cti2.1064","article-title":"Chimeric antigen receptors designed to overcome transforming growth factor-beta-mediated repression in the adoptive T-cell therapy of solid tumors","volume":"8","author":"Hartley","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fimmu.2019.00218","article-title":"Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors","volume":"10","author":"DeRenzo","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ijc.2910280307","article-title":"Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies","volume":"28","author":"Wilson","year":"1981","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00205360","article-title":"Immunochemical characterization of a human high molecular weight--melanoma associated antigen identified with monoclonal antibodies","volume":"14","author":"Wilson","year":"1983","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.7150\/thno.10824","article-title":"Theranostic impact of NG2\/CSPG4 proteoglycan in cancer","volume":"5","author":"Nicolosi","year":"2015","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380890-5.00003-X","article-title":"Functional and clinical relevance of chondroitin sulfate proteoglycan 4","volume":"109","author":"Campoli","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1755-148X.2011.00929.x","article-title":"CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma","volume":"24","author":"Price","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1083\/jcb.114.2.359","article-title":"The primary structure of NG2, a novel membrane-spanning proteoglycan","volume":"114","author":"Nishiyama","year":"1991","journal-title":"J. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1091\/mbc.e04-03-0236","article-title":"NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin","volume":"15","author":"Fukushi","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/bcr2895","article-title":"Chondroitin sulfates play a major role in breast cancer metastasis: A role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells","volume":"13","author":"Cooney","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1083\/jcb.200612084","article-title":"Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration","volume":"178","author":"Makagiansar","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G","article-title":"The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2","volume":"79","author":"Barritt","year":"2000","journal-title":"J. Cell Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.1074\/jbc.M706074200","article-title":"Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells","volume":"283","author":"Chatterjee","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.0.CO;2-M","article-title":"Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF","volume":"43","author":"Nishiyama","year":"1996","journal-title":"J. Neurosci. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1083\/jcb.200403174","article-title":"Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms","volume":"165","author":"Yang","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1038\/onc.2008.157","article-title":"The progenitor cell marker NG2\/MPG promotes chemoresistance by activation of integrin-dependent PI3K\/Akt signaling","volume":"27","author":"Chekenya","year":"2008","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3389\/fimmu.2017.01911","article-title":"Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types","volume":"8","author":"Ilieva","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Schiffer, D., Mellai, M., Boldorini, R., Bisogno, I., Grifoni, S., Corona, C., Bertero, L., Cassoni, P., Casalone, C., and Annovazzi, L. (2018). The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092724"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.placenta.2013.07.065","article-title":"The chrondroitin sulfate proteoglycan (CSPG4) regulates human trophoblast function","volume":"34","author":"Cuman","year":"2013","journal-title":"Placenta"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sakry, D., Neitz, A., Singh, J., Frischknecht, R., Marongiu, D., Biname, F., Perera, S.S., Endres, K., Lutz, B., and Radyushkin, K. (2014). Oligodendrocyte precursor cells modulate the neuronal network by activity-dependent ectodomain cleavage of glial NG2. PLoS Biol., 12.","DOI":"10.1371\/journal.pbio.1001993"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1242\/dev.00837","article-title":"Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis","volume":"130","author":"Legg","year":"2003","journal-title":"Development"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, J., Svendsen, A., Kmiecik, J., Immervoll, H., Skaftnesmo, K.O., Planaguma, J., Reed, R.K., Bjerkvig, R., Miletic, H., and Enger, P.O. (2011). Targeting the NG2\/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023062"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.1158\/0008-5472.CAN-10-1134","article-title":"Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0560.1988.tb00544.x","article-title":"Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors","volume":"15","author":"Wick","year":"1988","journal-title":"J. Cutan. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children\u2019s Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-017-2693-4","article-title":"Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: A meta-analysis","volume":"137","author":"Yang","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/ijc.28906","article-title":"Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients","volume":"135","author":"Warta","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.celrep.2016.06.058","article-title":"Mesenchymal Tumors Can Derive from Ng2\/Cspg4-Expressing Pericytes with beta-Catenin Modulating the Neoplastic Phenotype","volume":"16","author":"Sato","year":"2016","journal-title":"Cell Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","article-title":"HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD\/SCID IL2 Receptor Knockout Mice","volume":"79","author":"Forsberg","year":"2019","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1002\/acg2.11","article-title":"CAR T cells targeting alphavbeta3 integrin are effective against advanced cancer in preclinical models","volume":"1","author":"Wallstabe","year":"2018","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-10-0043","article-title":"Anti-GD3 chimeric sFv-CD28\/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors","volume":"16","author":"Lo","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1073\/pnas.1009069108","article-title":"Eradication of melanomas by targeted elimination of a minor subset of tumor cells","volume":"108","author":"Schmidt","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CJI.0000000000000061","article-title":"BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro","volume":"38","author":"Gargett","year":"2015","journal-title":"J. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.cmr.0000130874.33504.2f","article-title":"Her2\/neu is not a commonly expressed therapeutic target in melanoma\u2014A large cohort tissue microarray study","volume":"14","author":"Kluger","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bjc.2015.412","article-title":"Melanoma-expressed CD70 is involved in invasion and metastasis","volume":"114","author":"Pich","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.437","article-title":"Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells","volume":"3","author":"Schlaak","year":"2012","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jmcb\/mjt010","article-title":"NG2\/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion","volume":"5","author":"Cattaruzza","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/70302","article-title":"Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas","volume":"1","author":"Eisenmann","year":"1999","journal-title":"Nat. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/0008-5472.CAN-08-4626","article-title":"Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/BJ20061176","article-title":"Cell surface chondroitin sulfate glycosaminoglycan in melanoma: Role in the activation of pro-MMP-2 (pro-gelatinase A)","volume":"403","author":"Iida","year":"2007","journal-title":"Biochem. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12026-011-8232-z","article-title":"The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells","volume":"50","author":"Yu","year":"2011","journal-title":"Immunol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dorrie, J., Babalija, L., Hoyer, S., Gerer, K.F., Schuler, G., Heinzerling, L., and Schaft, N. (2018). BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010289"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-13-1253","article-title":"Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy","volume":"19","author":"Beard","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-2218","article-title":"T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo","volume":"20","author":"Geldres","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_60","first-page":"1393","article-title":"Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds","volume":"136","author":"Schlingemann","year":"1990","journal-title":"Am. J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00262-015-1767-4","article-title":"Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone","volume":"64","author":"Krug","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wiesinger, M., Marz, J., Kummer, M., Schuler, G., Dorrie, J., Schuler-Thurner, B., and Schaft, N. (2019). Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance. Cancers, 11.","DOI":"10.3390\/cancers11081198"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/HS9.0000000000000172","article-title":"CAR T Cells: A Snapshot on the Growing Options to Design a CAR","volume":"3","author":"Holzinger","year":"2019","journal-title":"Hemasphere"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12278","DOI":"10.1039\/c3nr04268e","article-title":"Antibody-drug conjugates: Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin","volume":"5","author":"Falvo","year":"2013","journal-title":"Nanoscale"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/ajh.25457","article-title":"Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia","volume":"94","author":"Bair","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood-2010-10-311845","article-title":"In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor","volume":"117","author":"Marin","year":"2011","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","article-title":"Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells","volume":"128","author":"Faitschuk","year":"2016","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy","volume":"134","author":"Martens","year":"2019","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","article-title":"Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: How close to reality?","volume":"104","author":"Cummins","year":"2019","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood.V87.3.1123.bloodjournal8731123","article-title":"The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23","volume":"87","author":"Smith","year":"1996","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Harrer, D.C., Schuler, G., Dorrie, J., and Schaft, N. (2019). CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112764"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.21037\/tcr.2016.08.15","article-title":"Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy","volume":"5","author":"Perna","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front. Pediatr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2017.294","article-title":"NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL","volume":"32","author":"Prieto","year":"2018","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41375-018-0353-0","article-title":"NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia","volume":"33","author":"Molina","year":"2019","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-11-1669","article-title":"Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells","volume":"18","author":"Brown","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/febs.14967","article-title":"Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance","volume":"286","author":"Vitale","year":"2019","journal-title":"FEBS J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2990.2002.00412.x","article-title":"The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours","volume":"28","author":"Chekenya","year":"2002","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1096\/fj.01-0632fje","article-title":"NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin","volume":"16","author":"Chekenya","year":"2002","journal-title":"FASEB J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/ptr.6363","article-title":"Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription","volume":"33","author":"Chen","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaao2731","DOI":"10.1126\/scitranslmed.aao2731","article-title":"Constitutive and TNFalpha-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy","volume":"10","author":"Pellegatta","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00401-011-0867-2","article-title":"Expression of the progenitor marker NG2\/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma","volume":"122","author":"Svendsen","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1615\/CritRevOncog.2017021307","article-title":"Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes","volume":"21","author":"Walsh","year":"2016","journal-title":"Crit. Rev. Oncog."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Tozbikian, G., Brogi, E., Kadota, K., Catalano, J., Akram, M., Patil, S., Ho, A.Y., Reis-Filho, J.S., Weigelt, B., and Norton, L. (2014). Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114900"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","article-title":"TEM8\/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer","volume":"78","author":"Byrd","year":"2018","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"126345","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Specht, J.M., Lee, S., Turtle, C.J., Berger, C., Baladrishnan, A., Srivastava, S., Voillet, V., Veatch, J., Gooley, T., and Mullane, E. (2018). Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR). Cancer Res., 78.","DOI":"10.1158\/1538-7445.AM2018-CT131"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jnci\/djq343","article-title":"CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer","volume":"102","author":"Wang","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2013.10.093","article-title":"High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer","volume":"441","author":"Hsu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000492392","article-title":"Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology","volume":"85","author":"Lee","year":"2018","journal-title":"Pathobiology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/mc.20854","article-title":"Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion","volume":"51","author":"Welte","year":"2012","journal-title":"Mol. Carcinog."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr3174","article-title":"Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan","volume":"14","author":"Gibby","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.molonc.2010.04.001","article-title":"Genomic instability in breast cancer: Pathogenesis and clinical implications","volume":"4","author":"Kwei","year":"2010","journal-title":"Mol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10456-013-9378-1","article-title":"NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function","volume":"17","author":"You","year":"2014","journal-title":"Angiogenesis"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/23\/5942\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:37:33Z","timestamp":1760189853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/23\/5942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":124,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["ijms20235942"],"URL":"https:\/\/doi.org\/10.3390\/ijms20235942","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]}}}